Victoria Kindt, PhD, is an experienced pharmaceutical toxicologist, specializing in the non-clinical development of small molecules. Based on a solid background in toxicity testing and compound development at Merck & Co., Dr. Kindt has successfully supported five IND filings since becoming a consultant in 2006.
Dr. Kindt has extensive experience in the design, management, interpretation, and documentation of non-clinical toxicity studies and the preparation of regulatory documents. She also developed drug development strategies for numerous small-molecule pharmaceuticals and has worked successfully with numerous project managers, training/assisting them in drug development strategies, non-clinical testing program design, and regulatory submissions. Vikki also managed a large non-clinical testing facility that conducted rodent studies of up to two years duration (carcinogenicity studies) and large animal (dog, primate) studies of up to one year duration.
Dr. Kindt is an experienced and respected drug safety expert with extensive background in drug development. She enjoys scientific problem solving. Her excellent communication skills and her natural negotiating abilities have helped her to move projects forward quickly and to build strong working relationships with clients and other professionals, at all levels.
Dr. Kindt holds a B.A. in Biology from Swarthmore College and a PhD in Toxicology from Rutgers University. She also completed her postdoctoral study in neurotoxicology at the University of Medicine and Dentistry of New Jersey. She is a member of the Society of Toxicology, the Mid-Atlantic Society of Toxicology and the Genetic Toxicology Association.
Pathways Toxicology Consulting